Universal Technical Institute, Inc.
Universal Technical Institute, Inc. (UTI) Stock Competitors & Peer Comparison
See (UTI) competitors and their performances in Stock Market.
Peer Comparison Table: Education & Training Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| UTI | $31.72 | +0.02% | 1.7B | 31.85 | $0.96 | N/A |
| EDU | $59.78 | +0.00% | 9.6B | 25.10 | $2.40 | +0.96% |
| TAL | $10.91 | +0.00% | 6.7B | 22.82 | $0.48 | N/A |
| LAUR | $33.99 | +0.00% | 4.8B | 24.32 | $1.35 | N/A |
| GHC | $1,080.31 | -0.00% | 4.8B | 6.62 | $165.62 | +0.67% |
| LOPE | $154.60 | +0.00% | 4.4B | 21.20 | $7.42 | N/A |
| LRN | $82.94 | +0.00% | 3.6B | 12.69 | $6.51 | N/A |
| ATGE | $96.75 | +0.00% | 3.5B | 14.24 | $6.79 | N/A |
| MH | $13.27 | +0.00% | 2.6B | -37.08 | -$0.37 | N/A |
| PRDO | $31.53 | +0.00% | 2.1B | 14.09 | $2.33 | +1.67% |
Stock Comparison
UTI vs EDU Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, EDU has a market cap of 9.6B. Regarding current trading prices, UTI is priced at $31.72, while EDU trades at $59.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas EDU's P/E ratio is 25.10. In terms of profitability, UTI's ROE is +0.17%, compared to EDU's ROE of +0.10%. Regarding short-term risk, UTI is more volatile compared to EDU. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check EDU's competition here
UTI vs TAL Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, TAL has a market cap of 6.7B. Regarding current trading prices, UTI is priced at $31.72, while TAL trades at $10.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas TAL's P/E ratio is 22.82. In terms of profitability, UTI's ROE is +0.17%, compared to TAL's ROE of +0.08%. Regarding short-term risk, UTI is more volatile compared to TAL. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check TAL's competition here
UTI vs LAUR Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, LAUR has a market cap of 4.8B. Regarding current trading prices, UTI is priced at $31.72, while LAUR trades at $33.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas LAUR's P/E ratio is 24.32. In terms of profitability, UTI's ROE is +0.17%, compared to LAUR's ROE of +0.26%. Regarding short-term risk, UTI is less volatile compared to LAUR. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check LAUR's competition here
UTI vs GHC Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, GHC has a market cap of 4.8B. Regarding current trading prices, UTI is priced at $31.72, while GHC trades at $1,080.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas GHC's P/E ratio is 6.62. In terms of profitability, UTI's ROE is +0.17%, compared to GHC's ROE of +0.17%. Regarding short-term risk, UTI is more volatile compared to GHC. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check GHC's competition here
UTI vs LOPE Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, LOPE has a market cap of 4.4B. Regarding current trading prices, UTI is priced at $31.72, while LOPE trades at $154.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas LOPE's P/E ratio is 21.20. In terms of profitability, UTI's ROE is +0.17%, compared to LOPE's ROE of +0.28%. Regarding short-term risk, UTI is less volatile compared to LOPE. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check LOPE's competition here
UTI vs LRN Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, LRN has a market cap of 3.6B. Regarding current trading prices, UTI is priced at $31.72, while LRN trades at $82.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas LRN's P/E ratio is 12.69. In terms of profitability, UTI's ROE is +0.17%, compared to LRN's ROE of +0.21%. Regarding short-term risk, UTI is less volatile compared to LRN. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check LRN's competition here
UTI vs ATGE Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, ATGE has a market cap of 3.5B. Regarding current trading prices, UTI is priced at $31.72, while ATGE trades at $96.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas ATGE's P/E ratio is 14.24. In terms of profitability, UTI's ROE is +0.17%, compared to ATGE's ROE of +0.18%. Regarding short-term risk, UTI is more volatile compared to ATGE. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check ATGE's competition here
UTI vs MH Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, MH has a market cap of 2.6B. Regarding current trading prices, UTI is priced at $31.72, while MH trades at $13.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas MH's P/E ratio is -37.08. In terms of profitability, UTI's ROE is +0.17%, compared to MH's ROE of -0.13%. Regarding short-term risk, UTI is less volatile compared to MH. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check MH's competition here
UTI vs PRDO Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, PRDO has a market cap of 2.1B. Regarding current trading prices, UTI is priced at $31.72, while PRDO trades at $31.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas PRDO's P/E ratio is 14.09. In terms of profitability, UTI's ROE is +0.17%, compared to PRDO's ROE of +0.16%. Regarding short-term risk, UTI is less volatile compared to PRDO. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check PRDO's competition here
UTI vs STRA Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, STRA has a market cap of 1.8B. Regarding current trading prices, UTI is priced at $31.72, while STRA trades at $75.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas STRA's P/E ratio is 15.83. In terms of profitability, UTI's ROE is +0.17%, compared to STRA's ROE of +0.07%. Regarding short-term risk, UTI is more volatile compared to STRA. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check STRA's competition here
UTI vs AFYA Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, AFYA has a market cap of 1.3B. Regarding current trading prices, UTI is priced at $31.72, while AFYA trades at $13.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas AFYA's P/E ratio is 9.22. In terms of profitability, UTI's ROE is +0.17%, compared to AFYA's ROE of +0.16%. Regarding short-term risk, UTI is more volatile compared to AFYA. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check AFYA's competition here
UTI vs DAO Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, DAO has a market cap of 1.2B. Regarding current trading prices, UTI is priced at $31.72, while DAO trades at $9.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas DAO's P/E ratio is 59.91. In terms of profitability, UTI's ROE is +0.17%, compared to DAO's ROE of -0.05%. Regarding short-term risk, UTI is less volatile compared to DAO. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check DAO's competition here
UTI vs PXED Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, PXED has a market cap of 1.1B. Regarding current trading prices, UTI is priced at $31.72, while PXED trades at $29.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas PXED's P/E ratio is 10.33. In terms of profitability, UTI's ROE is +0.17%, compared to PXED's ROE of +0.33%. Regarding short-term risk, UTI is less volatile compared to PXED. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check PXED's competition here
UTI vs COUR Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, COUR has a market cap of 1B. Regarding current trading prices, UTI is priced at $31.72, while COUR trades at $6.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas COUR's P/E ratio is -19.47. In terms of profitability, UTI's ROE is +0.17%, compared to COUR's ROE of -0.08%. Regarding short-term risk, UTI is less volatile compared to COUR. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check COUR's competition here
UTI vs LINC Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, LINC has a market cap of 948.4M. Regarding current trading prices, UTI is priced at $31.72, while LINC trades at $31.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas LINC's P/E ratio is 66.64. In terms of profitability, UTI's ROE is +0.17%, compared to LINC's ROE of +0.08%. Regarding short-term risk, UTI is less volatile compared to LINC. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check LINC's competition here
UTI vs ARCE Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, ARCE has a market cap of 927.4M. Regarding current trading prices, UTI is priced at $31.72, while ARCE trades at $13.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas ARCE's P/E ratio is -73.58. In terms of profitability, UTI's ROE is +0.17%, compared to ARCE's ROE of +0.02%. Regarding short-term risk, UTI is more volatile compared to ARCE. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check ARCE's competition here
UTI vs QSG Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, QSG has a market cap of 822.3M. Regarding current trading prices, UTI is priced at $31.72, while QSG trades at $5.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas QSG's P/E ratio is 5.54. In terms of profitability, UTI's ROE is +0.17%, compared to QSG's ROE of +0.38%. Regarding short-term risk, UTI is less volatile compared to QSG. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check QSG's competition here
UTI vs APEI Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, APEI has a market cap of 793M. Regarding current trading prices, UTI is priced at $31.72, while APEI trades at $43.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas APEI's P/E ratio is 33.47. In terms of profitability, UTI's ROE is +0.17%, compared to APEI's ROE of +0.11%. Regarding short-term risk, UTI is less volatile compared to APEI. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check APEI's competition here
UTI vs GOTU Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, GOTU has a market cap of 774.6M. Regarding current trading prices, UTI is priced at $31.72, while GOTU trades at $2.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas GOTU's P/E ratio is -9.64. In terms of profitability, UTI's ROE is +0.17%, compared to GOTU's ROE of -0.22%. Regarding short-term risk, UTI is more volatile compared to GOTU. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check GOTU's competition here
UTI vs REDU Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, REDU has a market cap of 730.3M. Regarding current trading prices, UTI is priced at $31.72, while REDU trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas REDU's P/E ratio is -23.04. In terms of profitability, UTI's ROE is +0.17%, compared to REDU's ROE of +0.15%. Regarding short-term risk, UTI is less volatile compared to REDU. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check REDU's competition here
UTI vs UDMY Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, UDMY has a market cap of 699.7M. Regarding current trading prices, UTI is priced at $31.72, while UDMY trades at $4.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas UDMY's P/E ratio is 159.33. In terms of profitability, UTI's ROE is +0.17%, compared to UDMY's ROE of +0.02%. Regarding short-term risk, UTI is less volatile compared to UDMY. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check UDMY's competition here
UTI vs KLC Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, KLC has a market cap of 496.8M. Regarding current trading prices, UTI is priced at $31.72, while KLC trades at $4.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas KLC's P/E ratio is -5.38. In terms of profitability, UTI's ROE is +0.17%, compared to KLC's ROE of -0.08%. Regarding short-term risk, UTI is less volatile compared to KLC. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check KLC's competition here
UTI vs VSTA Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, VSTA has a market cap of 394M. Regarding current trading prices, UTI is priced at $31.72, while VSTA trades at $4.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas VSTA's P/E ratio is 4.22. In terms of profitability, UTI's ROE is +0.17%, compared to VSTA's ROE of +0.10%. Regarding short-term risk, UTI is more volatile compared to VSTA. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check VSTA's competition here
UTI vs VTRU Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, VTRU has a market cap of 304.2M. Regarding current trading prices, UTI is priced at $31.72, while VTRU trades at $9.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas VTRU's P/E ratio is 15.91. In terms of profitability, UTI's ROE is +0.17%, compared to VTRU's ROE of +0.05%. Regarding short-term risk, UTI is more volatile compared to VTRU. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check VTRU's competition here
UTI vs LGCY Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, LGCY has a market cap of 159.1M. Regarding current trading prices, UTI is priced at $31.72, while LGCY trades at $12.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas LGCY's P/E ratio is 21.02. In terms of profitability, UTI's ROE is +0.17%, compared to LGCY's ROE of +0.19%. Regarding short-term risk, UTI is less volatile compared to LGCY. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check LGCY's competition here
UTI vs YOUL Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, YOUL has a market cap of 87.5M. Regarding current trading prices, UTI is priced at $31.72, while YOUL trades at $1.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas YOUL's P/E ratio is -38.33. In terms of profitability, UTI's ROE is +0.17%, compared to YOUL's ROE of +0.13%. Regarding short-term risk, UTI is less volatile compared to YOUL. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check YOUL's competition here
UTI vs LFS Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, LFS has a market cap of 71M. Regarding current trading prices, UTI is priced at $31.72, while LFS trades at $2.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas LFS's P/E ratio is 24.68. In terms of profitability, UTI's ROE is +0.17%, compared to LFS's ROE of +0.36%. Regarding short-term risk, UTI is less volatile compared to LFS. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check LFS's competition here
UTI vs CHGG Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, CHGG has a market cap of 67.7M. Regarding current trading prices, UTI is priced at $31.72, while CHGG trades at $0.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas CHGG's P/E ratio is -0.65. In terms of profitability, UTI's ROE is +0.17%, compared to CHGG's ROE of -0.68%. Regarding short-term risk, UTI is less volatile compared to CHGG. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check CHGG's competition here
UTI vs BEDU Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, BEDU has a market cap of 66.8M. Regarding current trading prices, UTI is priced at $31.72, while BEDU trades at $2.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas BEDU's P/E ratio is -0.55. In terms of profitability, UTI's ROE is +0.17%, compared to BEDU's ROE of -2.57%. Regarding short-term risk, UTI is more volatile compared to BEDU. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check BEDU's competition here
UTI vs STG Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, STG has a market cap of 60.8M. Regarding current trading prices, UTI is priced at $31.72, while STG trades at $4.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas STG's P/E ratio is 1.09. In terms of profitability, UTI's ROE is +0.17%, compared to STG's ROE of +0.52%. Regarding short-term risk, UTI is more volatile compared to STG. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check STG's competition here
UTI vs ONE Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, ONE has a market cap of 51.3M. Regarding current trading prices, UTI is priced at $31.72, while ONE trades at $1.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas ONE's P/E ratio is N/A. In terms of profitability, UTI's ROE is +0.17%, compared to ONE's ROE of +2.36%. Regarding short-term risk, UTI is less volatile compared to ONE. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check ONE's competition here
UTI vs SKIL Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, SKIL has a market cap of 45M. Regarding current trading prices, UTI is priced at $31.72, while SKIL trades at $5.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas SKIL's P/E ratio is -0.32. In terms of profitability, UTI's ROE is +0.17%, compared to SKIL's ROE of -2.65%. Regarding short-term risk, UTI is less volatile compared to SKIL. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check SKIL's competition here
UTI vs AIU Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, AIU has a market cap of 37.6M. Regarding current trading prices, UTI is priced at $31.72, while AIU trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas AIU's P/E ratio is 0.51. In terms of profitability, UTI's ROE is +0.17%, compared to AIU's ROE of -1.90%. Regarding short-term risk, UTI is less volatile compared to AIU. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check AIU's competition here
UTI vs RYET Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, RYET has a market cap of 35M. Regarding current trading prices, UTI is priced at $31.72, while RYET trades at $0.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas RYET's P/E ratio is -102.00. In terms of profitability, UTI's ROE is +0.17%, compared to RYET's ROE of -10.11%. Regarding short-term risk, UTI is more volatile compared to RYET. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check RYET's competition here
UTI vs GNS Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, GNS has a market cap of 33.5M. Regarding current trading prices, UTI is priced at $31.72, while GNS trades at $0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas GNS's P/E ratio is -0.72. In terms of profitability, UTI's ROE is +0.17%, compared to GNS's ROE of -0.51%. Regarding short-term risk, UTI is less volatile compared to GNS. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check GNS's competition here
UTI vs YQ Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, YQ has a market cap of 31.8M. Regarding current trading prices, UTI is priced at $31.72, while YQ trades at $3.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas YQ's P/E ratio is -2.60. In terms of profitability, UTI's ROE is +0.17%, compared to YQ's ROE of -0.46%. Regarding short-term risk, UTI is more volatile compared to YQ. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check YQ's competition here
UTI vs JZ Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, JZ has a market cap of 18.5M. Regarding current trading prices, UTI is priced at $31.72, while JZ trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas JZ's P/E ratio is -0.20. In terms of profitability, UTI's ROE is +0.17%, compared to JZ's ROE of -846.41%. Regarding short-term risk, UTI is less volatile compared to JZ. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check JZ's competition here
UTI vs IH Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, IH has a market cap of 18.4M. Regarding current trading prices, UTI is priced at $31.72, while IH trades at $1.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas IH's P/E ratio is 6.36. In terms of profitability, UTI's ROE is +0.17%, compared to IH's ROE of +0.11%. Regarding short-term risk, UTI is less volatile compared to IH. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check IH's competition here
UTI vs GEHI Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, GEHI has a market cap of 18.3M. Regarding current trading prices, UTI is priced at $31.72, while GEHI trades at $13.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas GEHI's P/E ratio is -0.24. In terms of profitability, UTI's ROE is +0.17%, compared to GEHI's ROE of -0.90%. Regarding short-term risk, UTI is less volatile compared to GEHI. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check GEHI's competition here
UTI vs AACG Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, AACG has a market cap of 14.2M. Regarding current trading prices, UTI is priced at $31.72, while AACG trades at $0.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas AACG's P/E ratio is -22.28. In terms of profitability, UTI's ROE is +0.17%, compared to AACG's ROE of -0.13%. Regarding short-term risk, UTI is less volatile compared to AACG. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check AACG's competition here
UTI vs EDTK Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, EDTK has a market cap of 13.7M. Regarding current trading prices, UTI is priced at $31.72, while EDTK trades at $0.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas EDTK's P/E ratio is -10.77. In terms of profitability, UTI's ROE is +0.17%, compared to EDTK's ROE of -0.19%. Regarding short-term risk, UTI is more volatile compared to EDTK. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check EDTK's competition here
UTI vs TEDU Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, TEDU has a market cap of 12.2M. Regarding current trading prices, UTI is priced at $31.72, while TEDU trades at $1.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas TEDU's P/E ratio is -2.40. In terms of profitability, UTI's ROE is +0.17%, compared to TEDU's ROE of -0.05%. Regarding short-term risk, UTI is less volatile compared to TEDU. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check TEDU's competition here
UTI vs BTCT Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, BTCT has a market cap of 11.3M. Regarding current trading prices, UTI is priced at $31.72, while BTCT trades at $1.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas BTCT's P/E ratio is -1.53. In terms of profitability, UTI's ROE is +0.17%, compared to BTCT's ROE of -0.24%. Regarding short-term risk, UTI is more volatile compared to BTCT. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check BTCT's competition here
UTI vs VEDU Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, VEDU has a market cap of 9.3M. Regarding current trading prices, UTI is priced at $31.72, while VEDU trades at $0.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas VEDU's P/E ratio is -1.91. In terms of profitability, UTI's ROE is +0.17%, compared to VEDU's ROE of -0.43%. Regarding short-term risk, UTI is less volatile compared to VEDU. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check VEDU's competition here
UTI vs WAFU Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, WAFU has a market cap of 7.5M. Regarding current trading prices, UTI is priced at $31.72, while WAFU trades at $1.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas WAFU's P/E ratio is -15.45. In terms of profitability, UTI's ROE is +0.17%, compared to WAFU's ROE of -0.04%. Regarding short-term risk, UTI is more volatile compared to WAFU. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check WAFU's competition here
UTI vs TCTM Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, TCTM has a market cap of 4.9M. Regarding current trading prices, UTI is priced at $31.72, while TCTM trades at $0.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas TCTM's P/E ratio is -0.15. In terms of profitability, UTI's ROE is +0.17%, compared to TCTM's ROE of -0.01%. Regarding short-term risk, UTI is less volatile compared to TCTM. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check TCTM's competition here
UTI vs ASPU Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, ASPU has a market cap of 4.6M. Regarding current trading prices, UTI is priced at $31.72, while ASPU trades at $0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas ASPU's P/E ratio is -0.40. In terms of profitability, UTI's ROE is +0.17%, compared to ASPU's ROE of +0.12%. Regarding short-term risk, UTI is less volatile compared to ASPU. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check ASPU's competition here
UTI vs TWOU Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, TWOU has a market cap of 4.4M. Regarding current trading prices, UTI is priced at $31.72, while TWOU trades at $1.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas TWOU's P/E ratio is -0.01. In terms of profitability, UTI's ROE is +0.17%, compared to TWOU's ROE of -0.88%. Regarding short-term risk, UTI is less volatile compared to TWOU. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check TWOU's competition here
UTI vs GV Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, GV has a market cap of 4.4M. Regarding current trading prices, UTI is priced at $31.72, while GV trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas GV's P/E ratio is -0.28. In terms of profitability, UTI's ROE is +0.17%, compared to GV's ROE of -1.71%. Regarding short-term risk, UTI is less volatile compared to GV. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check GV's competition here
UTI vs FCHL Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, FCHL has a market cap of 3.6M. Regarding current trading prices, UTI is priced at $31.72, while FCHL trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas FCHL's P/E ratio is -21.21. In terms of profitability, UTI's ROE is +0.17%, compared to FCHL's ROE of +2.18%. Regarding short-term risk, UTI is less volatile compared to FCHL. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check FCHL's competition here
UTI vs CLEU Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, CLEU has a market cap of 3.5M. Regarding current trading prices, UTI is priced at $31.72, while CLEU trades at $1.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas CLEU's P/E ratio is -0.00. In terms of profitability, UTI's ROE is +0.17%, compared to CLEU's ROE of -0.08%. Regarding short-term risk, UTI is less volatile compared to CLEU. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check CLEU's competition here
UTI vs METX Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, METX has a market cap of 3.1M. Regarding current trading prices, UTI is priced at $31.72, while METX trades at $2.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas METX's P/E ratio is 0.79. In terms of profitability, UTI's ROE is +0.17%, compared to METX's ROE of -0.04%. Regarding short-term risk, UTI is less volatile compared to METX. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check METX's competition here
UTI vs EEIQ Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, EEIQ has a market cap of 2.5M. Regarding current trading prices, UTI is priced at $31.72, while EEIQ trades at $3.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas EEIQ's P/E ratio is -1.22. In terms of profitability, UTI's ROE is +0.17%, compared to EEIQ's ROE of -0.34%. Regarding short-term risk, UTI is less volatile compared to EEIQ. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check EEIQ's competition here
UTI vs MYND Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, MYND has a market cap of 2.1M. Regarding current trading prices, UTI is priced at $31.72, while MYND trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas MYND's P/E ratio is -0.25. In terms of profitability, UTI's ROE is +0.17%, compared to MYND's ROE of -1.26%. Regarding short-term risk, UTI is less volatile compared to MYND. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check MYND's competition here
UTI vs FEDU Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, FEDU has a market cap of 2.1M. Regarding current trading prices, UTI is priced at $31.72, while FEDU trades at $10.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas FEDU's P/E ratio is 16.80. In terms of profitability, UTI's ROE is +0.17%, compared to FEDU's ROE of -0.00%. Regarding short-term risk, UTI is more volatile compared to FEDU. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check FEDU's competition here
UTI vs GSUN Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, GSUN has a market cap of 2.1M. Regarding current trading prices, UTI is priced at $31.72, while GSUN trades at $1.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas GSUN's P/E ratio is -0.58. In terms of profitability, UTI's ROE is +0.17%, compared to GSUN's ROE of -1.90%. Regarding short-term risk, UTI is less volatile compared to GSUN. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check GSUN's competition here
UTI vs KIDZ Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, KIDZ has a market cap of 1.8M. Regarding current trading prices, UTI is priced at $31.72, while KIDZ trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas KIDZ's P/E ratio is -9.86. In terms of profitability, UTI's ROE is +0.17%, compared to KIDZ's ROE of +6.40%. Regarding short-term risk, UTI is less volatile compared to KIDZ. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check KIDZ's competition here
UTI vs VSA Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, VSA has a market cap of 1.5M. Regarding current trading prices, UTI is priced at $31.72, while VSA trades at $1.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas VSA's P/E ratio is -0.01. In terms of profitability, UTI's ROE is +0.17%, compared to VSA's ROE of +0.36%. Regarding short-term risk, UTI is less volatile compared to VSA. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check VSA's competition here
UTI vs RYB Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, RYB has a market cap of 1M. Regarding current trading prices, UTI is priced at $31.72, while RYB trades at $0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas RYB's P/E ratio is 1.87. In terms of profitability, UTI's ROE is +0.17%, compared to RYB's ROE of +0.05%. Regarding short-term risk, UTI is less volatile compared to RYB. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check RYB's competition here
UTI vs AMBO Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, AMBO has a market cap of 329.9K. Regarding current trading prices, UTI is priced at $31.72, while AMBO trades at $2.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas AMBO's P/E ratio is 3.35. In terms of profitability, UTI's ROE is +0.17%, compared to AMBO's ROE of +0.94%. Regarding short-term risk, UTI is less volatile compared to AMBO. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check AMBO's competition here
UTI vs KIDZW Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, KIDZW has a market cap of 183K. Regarding current trading prices, UTI is priced at $31.72, while KIDZW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas KIDZW's P/E ratio is N/A. In terms of profitability, UTI's ROE is +0.17%, compared to KIDZW's ROE of +6.40%. Regarding short-term risk, UTI is less volatile compared to KIDZW. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check KIDZW's competition here
UTI vs LXEH Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, LXEH has a market cap of 169.3K. Regarding current trading prices, UTI is priced at $31.72, while LXEH trades at $0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas LXEH's P/E ratio is -0.11. In terms of profitability, UTI's ROE is +0.17%, compared to LXEH's ROE of -0.20%. Regarding short-term risk, UTI is less volatile compared to LXEH. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check LXEH's competition here
UTI vs BTCTW Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, BTCTW has a market cap of 15.5K. Regarding current trading prices, UTI is priced at $31.72, while BTCTW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas BTCTW's P/E ratio is N/A. In terms of profitability, UTI's ROE is +0.17%, compared to BTCTW's ROE of -0.24%. Regarding short-term risk, UTI is less volatile compared to BTCTW. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check BTCTW's competition here
UTI vs GPX Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, GPX has a market cap of 0. Regarding current trading prices, UTI is priced at $31.72, while GPX trades at $20.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas GPX's P/E ratio is N/A. In terms of profitability, UTI's ROE is +0.17%, compared to GPX's ROE of +0.03%. Regarding short-term risk, UTI is more volatile compared to GPX. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check GPX's competition here
UTI vs HLG Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, HLG has a market cap of 0. Regarding current trading prices, UTI is priced at $31.72, while HLG trades at $14.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas HLG's P/E ratio is 5.29. In terms of profitability, UTI's ROE is +0.17%, compared to HLG's ROE of +0.11%. Regarding short-term risk, UTI is more volatile compared to HLG. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check HLG's competition here
UTI vs FHS Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, FHS has a market cap of 0. Regarding current trading prices, UTI is priced at $31.72, while FHS trades at $0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas FHS's P/E ratio is 0.55. In terms of profitability, UTI's ROE is +0.17%, compared to FHS's ROE of N/A. Regarding short-term risk, UTI is less volatile compared to FHS. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check FHS's competition here
UTI vs TTEI Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, TTEI has a market cap of 0. Regarding current trading prices, UTI is priced at $31.72, while TTEI trades at N/A.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas TTEI's P/E ratio is N/A. In terms of profitability, UTI's ROE is +0.17%, compared to TTEI's ROE of N/A. Regarding short-term risk, Volatility data is not available for a full comparison. UTI has daily volatility of 2.81 and TTEI has daily volatility of N/A.Check TTEI's competition here
UTI vs ZME Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, ZME has a market cap of 0. Regarding current trading prices, UTI is priced at $31.72, while ZME trades at $0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas ZME's P/E ratio is -0.00. In terms of profitability, UTI's ROE is +0.17%, compared to ZME's ROE of -1.88%. Regarding short-term risk, UTI is less volatile compared to ZME. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check ZME's competition here
UTI vs RSHL Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, RSHL has a market cap of 0. Regarding current trading prices, UTI is priced at $31.72, while RSHL trades at N/A.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas RSHL's P/E ratio is N/A. In terms of profitability, UTI's ROE is +0.17%, compared to RSHL's ROE of N/A. Regarding short-term risk, Volatility data is not available for a full comparison. UTI has daily volatility of 2.81 and RSHL has daily volatility of N/A.Check RSHL's competition here
UTI vs ZVO Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, ZVO has a market cap of 0. Regarding current trading prices, UTI is priced at $31.72, while ZVO trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas ZVO's P/E ratio is -0.08. In terms of profitability, UTI's ROE is +0.17%, compared to ZVO's ROE of -1.07%. Regarding short-term risk, UTI is less volatile compared to ZVO. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check ZVO's competition here
UTI vs NEW Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, NEW has a market cap of 0. Regarding current trading prices, UTI is priced at $31.72, while NEW trades at $1.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas NEW's P/E ratio is -0.55. In terms of profitability, UTI's ROE is +0.17%, compared to NEW's ROE of -0.09%. Regarding short-term risk, UTI is less volatile compared to NEW. This indicates potentially lower risk in terms of short-term price fluctuations for UTI.Check NEW's competition here
UTI vs HMHC Comparison February 2026
UTI plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UTI stands at 1.7B. In comparison, HMHC has a market cap of 0. Regarding current trading prices, UTI is priced at $31.72, while HMHC trades at $21.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UTI currently has a P/E ratio of 31.85, whereas HMHC's P/E ratio is 12.54. In terms of profitability, UTI's ROE is +0.17%, compared to HMHC's ROE of +0.01%. Regarding short-term risk, UTI is more volatile compared to HMHC. This indicates potentially higher risk in terms of short-term price fluctuations for UTI.Check HMHC's competition here